RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07109401, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pathologically (histologically or cytologically) confirmed diagnosis of small cell lung cancer;

    Inclusion criterion 3

  3. Receiving systemic corticosteroid therapy within 14 days prior to the first dose of study drug;

    Exclusion criterion 4

  4. ECOG PS score of 0-1;

    Inclusion criterion 6

  5. Any active malignancy within 2 years prior to enrollment;

    Exclusion criterion 6

  6. Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;

    Exclusion criterion 7

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07109401, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able to provide written informed consent and understand and agree to comply with the study requirements and assessment schedule;
  • Aged 18-75 years at the time of signing the informed consent form;
  • Pathologically (histologically or cytologically) confirmed diagnosis of small cell lung cancer;
  • Limited-stage disease (stage IIB-IIIB according to AJCC 8th edition) assessed by bronchoscopy, PET-CT, endobronchial ultrasound (EBUS), mediastinoscopy, or percutaneous biopsy, deemed resectable with curative intent (R0 resection) by the investigator.

TNM staging includes T3-4 (N0 only) or N1-2 (any T) and M0, where T4 is limited to tumors >7 cm in diameter; Patients with tumors invading the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina or having separate tumor nodules in different ipsilateral lobes are excluded. N2 is limited to single station and non-bulky.

  • No prior radiotherapy, chemotherapy, immunotherapy, surgery or other systemic treatments;
  • ECOG PS score of 0-1;
  • Expected survival must be >3 months;
  • Adequate bone marrow reserve and organ function within 30 days prior to enrollment meeting criteria for receiving platinum-based doublet chemotherapy;
  • No contraindications for immunotherapy.

Exclusion Criteria:

  • Tumor histopathology indicates non-small cell lung cancer (NSCLC);
  • Presence of clinically inactive or active brain metastases;
  • Any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), current ILD, or suspicion of such diseases based on imaging during screening;
  • Receiving systemic corticosteroid therapy within 14 days prior to the first dose of study drug;
  • Previous radiotherapy, chemotherapy, immunotherapy, surgery, or other systemic treatments;
  • Any active malignancy within 2 years prior to enrollment;
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
  • Uncontrolled or significant cardiovascular disease at the time of enrollment;
  • Active or previously recorded autoimmune or inflammatory diseases before enrollment;
  • History of active primary immunodeficiency disorders;
  • Presence of active infections;
  • Active bleeding disorders within ≤6 months prior to administration of the study drug, including gastrointestinal bleeding evidenced by hematemesis, severe hemoptysis, or melena;
  • Non-healing wounds, active peptic ulcers, or fractures;
  • Any condition that the investigator deems makes the patient unsuitable for participation in the study.

Quoted from ClinicalTrials.gov, NCT07109401, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07109401, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07109401